PLIANT THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
PLIANT THERAPEUTICS, INC. (PLRX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $842.00K, a 3.31% increase year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $835.00K, a 2.71% increase year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $828.00K, a 2.10% increase year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $821.00K, a 1.48% increase year-over-year.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $3.28M, a 5.04% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $3.45M, a 44.39% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.39M, a 28.63% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.86M, a 11.32% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $842.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.68M 10-Q · filed 2026-08-11 | $2.50M derived: sum of 3 quarters · filed 2026-08-11 | $3.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $835.00K 10-Q · filed 2026-05-11 | $1.66M derived: sum of 2 quarters · filed 2026-05-11 | $2.48M derived: sum of 3 quarters · filed 2026-05-11 | $3.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $828.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.65M derived: sum of 2 quarters · filed 2026-03-11 | $2.46M derived: sum of 3 quarters · filed 2026-08-11 | $3.28M 10-K · filed 2026-03-11 |
| 2025-09-30 | $821.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.64M derived: sum of 2 quarters · filed 2026-08-11 | $2.45M 10-Q · filed 2025-11-06 | $3.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $815.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.63M 10-Q · filed 2026-08-11 | $2.44M derived: sum of 3 quarters · filed 2026-08-11 | $3.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $813.00K 10-Q · filed 2026-05-11 | $1.62M derived: sum of 2 quarters · filed 2026-05-11 | $2.43M derived: sum of 3 quarters · filed 2026-05-11 | $3.58M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $811.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.62M derived: sum of 2 quarters · filed 2026-03-11 | $2.77M derived: sum of 3 quarters · filed 2026-03-11 | $3.45M 10-K · filed 2026-03-11 |
| 2024-09-30 | $809.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.96M derived: sum of 2 quarters · filed 2025-11-06 | $2.64M 10-Q · filed 2025-11-06 | $3.20M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.83M 10-Q · filed 2025-08-07 | $2.39M derived: sum of 3 quarters · filed 2025-08-07 | $2.98M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $681.00K 10-Q · filed 2025-05-08 | $1.24M derived: sum of 2 quarters · filed 2025-05-08 | $1.83M derived: sum of 3 quarters · filed 2025-05-08 | $2.46M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.15M derived: sum of 2 quarters · filed 2025-03-03 | $1.78M derived: sum of 3 quarters · filed 2025-03-03 | $2.39M 10-K · filed 2025-03-03 |
| 2023-09-30 | $597.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.22M derived: sum of 2 quarters · filed 2024-11-07 | $1.83M 10-Q · filed 2024-11-07 | $2.43M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.24M 10-Q · filed 2024-08-07 | $1.83M derived: sum of 3 quarters · filed 2025-03-03 | $2.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $609.00K 10-Q · filed 2024-05-06 | $1.21M derived: sum of 2 quarters · filed 2025-03-03 | $1.78M derived: sum of 3 quarters · filed 2025-03-03 | $2.22M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.17M derived: sum of 2 quarters · filed 2025-03-03 | $1.61M derived: sum of 3 quarters · filed 2025-03-03 | $1.86M 10-K · filed 2025-03-03 |
| 2022-09-30 | $576.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.02M derived: sum of 2 quarters · filed 2023-11-09 | $1.26M 10-Q · filed 2023-11-09 | $2.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $440.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $684.00K 10-Q · filed 2023-08-09 | $1.49M derived: sum of 3 quarters · filed 2024-02-27 | $1.91M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $244.00K 10-Q · filed 2023-05-09 | $1.05M derived: sum of 2 quarters · filed 2024-02-27 | $1.47M derived: sum of 3 quarters · filed 2024-02-27 | $1.56M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $806.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.23M derived: sum of 2 quarters · filed 2024-02-27 | $1.32M derived: sum of 3 quarters · filed 2024-02-27 | $1.67M 10-K · filed 2024-02-27 |
| 2021-09-30 | $422.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $515.00K derived: sum of 2 quarters · filed 2022-11-08 | $863.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $441.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $348.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |